Portugal INFARMED

Trodelvy (sacituzumab govitecano) – Public funding evaluation report available; positive assessment decision

Original title: Trodelvy (Sacituzumab govitecano) | Relatório de avaliação de financiamento público disponível na Infomed | Deferimento do pedido de avaliação prévia

INFARMED has granted a positive assessment for public funding of Trodelvy (sacituzumab govitecano).

Low obligation Product class Pharmaceuticals Market Access & Reimbursement Portugal PharmaceuticalsReimbursement

Data : 11/08/2026

Dates and deadlines

Applies from

2026-08-11

Read the official source ↗

Published by Portugal INFARMED. HealthSignal links to the original document; the summary above is extracted from the source text.